Kim's Eye Hospital
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1962-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://kimeye.com
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
Phase 4
Recruiting
- Conditions
- Age-related Macular Degeneration (ARMD)
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06683950
- Locations
- 🇰🇷
Kim's Eye Hospital, Seoul, Korea, Republic of
Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
Completed
- Conditions
- Polypoidal Choroidal VasculopathyChoroidal NeovascularizationAge-Related Macular Degeneration
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 135
- Registration Number
- NCT05662943
- Locations
- 🇰🇷
Jae Hui Kim, Seoul, Korea, Republic of
Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy
Phase 4
Not yet recruiting
- Conditions
- Pachychoroid Neovasculopathy
- Interventions
- Drug: Three monthly injections of intravitreal aflibercept
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05662410
Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion
Completed
- Conditions
- Age-related Macular Degeneration
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 512
- Registration Number
- NCT04836143
- Locations
- 🇰🇷
Jae Hui Kim, Seoul, Korea, Republic of
Treat-and-extend Using Aflibercept for Type 3 Neovascularization
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04655482
- Locations
- 🇰🇷
Jae Hui Kim, Seoul, Korea, Republic of
Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
Not Applicable
Completed
- Conditions
- Central Serous Chorioretinopathy
- Interventions
- Device: Selective retina therapy
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT03339856
Intravitreal Aflibercept for Submacular Hemorrhage
Phase 4
Completed
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- Drug: Vascular endothelial growth factor trap-eye
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT03169660
- Locations
- 🇰🇷
Kim's Eye Hospital, Seoul, Korea, Republic of
The High Cup/Disc Ratio in Children
Completed
- Conditions
- Glaucoma
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00825890
- Locations
- 🇰🇷
Kim's Eye Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath